Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Systems Ceases Development of Prostate Cancer Dx

NEW YORK (GenomeWeb News) – Australian firm Proteome Systems said today that it has stopped developing a protein biomarker-based test for prostate cancer because “the project did not satisfy internal assessment hurdles.”
The company said that it recently validated data generated by Egenix, which demonstrated that there is an increased expression of human carcinoma antigen in cancerous versus non-cancerous prostate tissues. The proof of concept study was aimed at evaluating the possibility of using a protein biomarker that provides specific detection of HCA in a semen-based test for prostate cancer.
However, Proteome Systems said that bringing the assay to market “would require significant resources along with an extended development timeline.”
The firm has a collaboration with Becton Dickinson to develop protein biomarkers for tuberculosis diagnostic products and an alliance with Bayer CropScience to use the firm’s DiagnostIQ device in defined agricultural fields.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.